Drug intelligence / Profile preview

nab-paclitaxel + ipilimumab

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

nab-paclitaxel + ipilimumab is a combination therapy evaluated for the treatment of metastatic melanoma. It consists of Abraxane (nab-paclitaxel), a nanoparticle albumin-bound formulation of the taxane paclitaxel, and Yervoy (ipilimumab), a recombinant human monoclonal antibody. Nab-paclitaxel functions as a cytotoxic chemotherapy agent by stabilizing microtubules and inhibiting cell division, while ipilimumab acts as an immune checkpoint inhibitor by targeting CTLA-4 to enhance T-cell activation and proliferation. This specific combination was investigated in a Phase II clinical trial (NCT01827111) led by the M.D. Anderson Cancer Center to assess safety and efficacy in patients with advanced or unresectable cutaneous or mucosal melanoma.

Brand names: AbraxaneYervoy
Other names: A-M.D. Anderson Cancer Center-melanomapaclitaxel albumin-boundnab-paclitaxelipilimumab

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + ipilimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + ipilimumab.

Explore the full profile